Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Betekom – page 50

1 978 clinical trials in Betekom, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Betekom at a glance
1 978
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 978 trials in Betekom

Open in trial search

Chondrosarcoma

Recruiting

Study of ivosidenib in adults with advanced or metastatic chondrosarcoma with IDH1 mutation who are untreated or have had one prior treatment

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Boehringer Ingelheim International GmbH

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Myelofibrosis+1

Recruiting

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Study on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Universitaetsklinikum Essen AöR

Long-Term Safety Study of BCMACP03, BCN-CP01, and 19CP02 for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, CLL, SLL, or Multiple Myeloma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BCMACP03
  • Sponsor:Lakefront Biotherapeutics

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Oral herpes+1

Recruiting

Study on the Effectiveness of 2LHERP in Reducing Recurrent Cold Sores in Patients with Frequent Outbreaks

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Ribonucleic Acid
  • Sponsor:Labo'Life Belgium

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Betekom

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on optimizing treatment strategies for patients with functional dyspepsia and related gastrointestinal conditions. This study explores effective methods for reducing long-term dependency on proton pump inhibitors (PPIs).

  • Medication De-prescribing Strategies
  • Gastrointestinal Health Management
  • Alternative Treatment Approaches

The research evaluates various therapeutic approaches, including on-demand medication use and alternative treatments, aiming to improve patient care in primary healthcare settings.

02 Primary Care Innovation

A groundbreaking study examining the effectiveness of different approaches to managing chronic acid reflux and heartburn symptoms. This research aims to establish more patient-centered treatment protocols.

  • Patient-Centered Care
  • Long-term Medication Management
  • Treatment Optimization

The trial explores innovative strategies to help patients safely reduce their dependence on long-term acid suppression therapy while maintaining symptom control.

03 Therapeutic Alternatives

Investigation into the comparative effectiveness of different treatment strategies for digestive disorders, including traditional medication tapering and alternative therapeutic approaches.

  • Medication Alternatives
  • Symptom Management
  • Quality of Life Impact

This research evaluates various therapeutic options, including alginate-based treatments, to provide evidence-based alternatives for long-term acid suppression therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.